Watch and Learn

On demand educational videos

All of the GVF meeting videos are listed below. If you want to see only videos from one of the meetings, click the appropriate button below.

David Rosmarin, MD

Invited Speaker: Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies

Prashant Giri, MSc

Altered Calcium-NFAT Signaling Pathway May Be Responsible for Decreased Suppressive Capacity of Tregs in Generalized Vitiligo Patients

Janice Nathalie, MD

Health-Related Quality of Life in Pediatric Patients With Vitiligo

Thierry Passeron, MD, PhD Oral Abstract

Increased Cutaneous Activation of Innate Immunity and Pro-apoptotic CXCR3B in Patients With Segmental Vitiligo

Davinder Parsad, MD

Invited Speaker: Stabilizing Treatment Options in Vitiligo

Andrew Thompson, DClinPsy

The Association Between Mental Health Conditions and Vitiligo: A Population-Based Cohort Study in the UK

Nanis Ragab, MD

Early Localized Vitiligo, a Medical Emergency: Long Term Follow up Study

Jessica Shiu, MD, PhD

Multimodal Analyses of Stable Vitiligo Skin Identify Tissue Interactions That Control Disease Persistence

Poster Session Q&A #3

Laila Benzekri, MD Avina Jain, MBBS, MD Reenu T. George, MD Prakhar Srivastava, MBBS, MD

Samia Esmat, MD

Vitiligo Treatment: Patient’s or Doctor's Decision ?!!

Rania Mogawer, MD

Efficacy of Narrow Band UVB With or Without Oral Mini-Pulse Steroids in Stabilization of Vitiligo Activity in Skin Phototypes (III -V): A Double Blind Randomized Placebo Controlled Prospective Multi-Center Study

Marissa Ceresnie, DO

Investigating Disparities in Recording Race and Ethnicity in Vitiligo Clinical Trial Screening Assessments

Monica Ottaviani, PhD

Vitiligo: The Skin Barrier Point of View

Jayvadan Vaishnav, MSc

Involvement of VTCN1 and Its Cleaving Enzyme NRD1 in Vitiligo Pathogenesis

Ahmed Mourad, MBBS, MS

Assessment of Tissue PD-1 and PD-l1 Levels in Vitiligo Patients (Case Control Study)

Poster Session Q&A #4

Sanjay Kumar Kanodia, MD Paras Choudhary, MD Nicoline Post, MD Alexandria Brown, BSA

Thierry Passeron, MD, PhD

Invited Speaker: Oral Gliadin-Protected Superoxide Dismutase in Addition to Phototherapy for Treating Non-segmental Vitiligo: A 24-Week Prospective Randomized Placebo-Controlled Study

Hyun Jeong Ju, MD

Progressive and Extensive Hypomelanosis of Childhood: A Novel Disease Entity Distinguished from Other Hypomelanotic Disorders

Marcella Willemsen, MSc

Immunophenotypic Analysis Reveals Differences in Circulating Immune Cells in Peripheral Blood of Segmental and Non-segmental Vitiligo Patients

Nanja van Geel, MD, PhD and Jolien Duponselle, MD

Image Analyses Systems to Calculate the Surface Area of Vitiligo Lesions: A Systematic Review of Measurement Properties

Caroline Le Poole, PhD

Invited Speaker: Modeling Microbial Impact on Autoimmune Depigmentation in Mice

Saurabh Bhatia, MD

Efficacy of NB-UVB in Progressive Versus Non-progressive Non-segmental Vitiligo: A Prospective Comparative Study

2021 VIS Khaled Ezzedine, MD, PhD

Efficacy and Safety of the Oral Janus Kinase 3/Tec Inhibitor Ritlecitinib (PF-06651600) In Adults With Active Non-segmental Vitiligo: Results From a Phase 2b, Randomized, Dose-Ranging Study With an Extension Period

Beth Schneider, PhD

Research - MyVitiligoTeam (Social Network)

Poster Q&A Session #1

Shiwangi Rana, MD; Alpana Mohta, MD; Ju Hee Han, MD; Fabiana Castro Porto Silva Lopes, MD;

Mauro Picardo, MD

Invited Speaker - Vitiligo: A Diverse Perspective

Nicoline Post, MD

Meek Micrografting: A Novel Surgical Technique for the Treatment of Depigmentation

Helen Kitchen, MSc

A Qualitative Study to Explore the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) Measures

Camille Robinson, BS

Assessment of Vitiligo Patients’ Perceptions and Opinions About Their Dermatologists When They Were First Diagnosed

Marcella Willemsen, MSc Invited Speaker

Vitiligo Up-and-Coming Invited Speaker: Impaired Ifn-γ-Induced PD-L1 Expression on Human Vitiligo Melanocytes

Poster Session Q&A #2

Lamia Elgarhy, MD; Yvon Gauthier, MD; Jalal Maghfour, MD; Nicole Syder, BA

Q&A Session #4

Iltefat H. Hamzavi, MD, FAAD – Invited Speaker

Phototherapy for Vitiligo: How to Optimize and What the Future Holds

Simone Nichole Boeckmann Montgomery, BA

Vitiligo and Psychological Comorbidities: A Retrospective Analysis in an Urban Population

Youwen Zhou, MD, PhD

Therapeutic Response Biomarkers for Vitiligo Patients on Narrow Band UVB and Topical Tacrolimus Combination Therapy

Haitham M. Saleh, Msc

A Comparative Pilot Study of Dipstick versus Open-Spray Cryotherapy Techniques as Depigmentation Treatments for Vitiligo

Davinder Parsad, MD

Recent Advances in the Surgical Management of Vitiligo

Q&A Session #3

Jung Min Bae, MD, PhD Oral Abstract

An Identification of Potential Therapeutics for Vitiligo by Mass Screening for 1,732 Medicines in Korean National Health Insurance Database

John E. Harris, MD, PhD – Oral Abstract

Survey Investigating the Prevalence of Vitiligo and Vitiligo Signs among Adults in Europe, Japan, and the United States

Saad Altalhab, MBBS

Risk Factors of Infection Post Non-cultured Melanocyte Keratinocyte Transplantation for Vitiligo


Advances in Treatment of Vitiligo With JAK Inhibitors

Meri K. Tulic, PhD

Analysis of Matched Skin and Gut Microbiome of Vitiligo Patients Reveals Dysbiosis in Lesional Skin: Association with Mitochondrial Damage and Changes in Immune Function

Victor Huang, MD

An Open-Label Pilot Study of Abatacept (CTLA4-Ig) for the Treatment of Nonsegmental Vitiligo

Iltefat H. Hamzavi, MD, FAAD Oral Abstract

Analysis of 24-Week Response to Ruxolitinib Cream for the Treatment of Vitiligo Based on Patient Demographics and Clinical Characteristics

Nanja van Geel, MD, PhD

International Collaborative Project to Standardize the Assessment and Monitoring of Vitiligo in Clinical Trials, Registries and Clinical Practice

Q&A Session #2

Julien Seneschal, MD, PHD

Vitiligo: Looking at the Memory T Cell Response

Jesslyn Alyce Magee, MS

Pilot Network Model for Automated Vitiligo Lesion Segmentation: Promise and Challenges

Nanja van Geel, MD, PhD – Oral Abstract

Influencing Factors on the Patient Global Assessment Score for Vitiligo Severity

Pearl Grimes, MD

Effects of Ruxolitinib Cream on Affected Body Areas in Patients with Vitiligo: Subgroup Analysis from a 52-Week, Randomized, Double-Blind Trial

John E. Harris, MD, PhD

Advances In Immune Mechanisms Of Vitiligo

Q&A Session #1

Chris O’Brien

Patient Stories, Data and Demo – MyVitiligoTeam (Patient Social Network)

Vidhya Shankar Narayan, MD

Donor to Recipient Ratios in the Surgical Treatment of Vitiligo and Piebaldism: A Systematic Review

Jung Min Bae, MD, PhD

Vitiligo and Comorbidity: A Comprehensive Review

Pankhuri Dudani, MBBS

Effects of Adding PRP to Microneedling Plus 5-Fluorouracil Therapy in Acral Vitiligo: A Split-Body Randomized Trial

Mahajabeen Saheb Patel Madarkar, MD

Comparative Study of Safety and Efficacy of Oral Betamethasone Pulse Therapy and Azathioprine in Vitiligo

Khaled Ezzedine, MD, PhD

Prevalence of Psychosocial Comorbidities in Vitiligo: A Systematic Literature Review

Richard A. Spritz, MD

Genetic And Environmental Correlates Of Vitiligo